Clinical Study

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Attack Study To Evaluate The Efficacy, Safety, Tolerability, And Pharmacokinetics Of Oral Ubrogepant In The Acute Treatment Of Migraine With Or Without Aura In Children And Adole

Posted Date: Jan 19, 2022

  • Investigator: Luis Patino Duran
  • Specialties:
  • Type of Study: Drug

Study drug for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)


Participants Must Be Between The Ages Of 6 And 17 Years (Inclusive), Have A History Of Migraine With Or Without Aura For At Least 6 Months


Acute Migraine, Children, Aura

For More Information:

Heather Williamson, Mcr

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.